Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema

Eye (Basingstoke)

Volumn 28, Issue 6, 2014, Pages 646-653

  Hanhart, J ^a   Tiosano, L ^a   Averbukh, E ^a   Banin, E ^a   Hemo, I ^a   Chowers, I ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; FOLLOW UP; HUMAN; LASER; LASER COAGULATION; MACULAR THICKNESS; MALE; OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY;

EID: 84928760171     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.94     Document Type: Article

References (23)

1. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.
2. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris 3rd FL, Friedman SM et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
3. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
4. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
5. Aiello LP, Beck RW, Bressler NM, Browning DJ, Chalam KV, Davis M et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 2011; 118: e5-14.
6. Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (Lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res 2012; 37: 661-670.
7. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-1218.
8. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153: 327-333.
9. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
10. Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina 2011; 31: 1871-1876.
11. Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009; 13: 400-402.
12. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1691-1695.
13. Meyer CH, Krohne TU, Holz FG. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 2012; 90: 68-70.
14. Scartozzi R, Chao JR, Walsh AC, Eliott D. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye 2009; 23: 1229.
15. Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers 3rd MB, Morales-Catón V, Quiroz-Mercado H. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 2009; 29: 20-26.
16. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008; 37: 591-593.
17. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182.
18. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 4807-4813.
19. Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol 2011; 5: 697-704.
20. Hosseini H, Lotfi M, Esfahani MH, Nassiri N, Khalili MR, Razeghinejad MR et al. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina 2012; 32: 967-971.
21. Gamulescu MA, Helbig H. Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 2010; 26: 213-216.
22. Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 2013; 29: 728-732.
23. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28: 1053-1060.